BioPharma Dive April 4, 2025
Big-ticket biotech buyouts have become scarce in recent months. U.S. policy upheaval threatens to keep it that way.
The world’s largest pharmaceutical companies mostly steered clear of billion-dollar acquisitions in the early months of this year, perhaps indicating how a tumultuous U.S. political environment has led would-be buyers to view bigger deals as too risky for the time being.
Two acquisitions worth $1 billion up front or more — that of psychiatry drugmaker Intra-Cellular Therapies and cancer specialist IDRx — were announced between January and March, according to BioPharma Dive data on the industry’s more sizable transactions.
By comparison, six billion-dollar-plus deals were inked during the same three-month period in 2024, though this year’s tally is not much lower than...
Today's Sponsors
Today's Sponsor